TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,864,120 | -47.6% | 1,215,226 | -10.0% | 0.00% | -50.0% |
| Q2 2023 | $20,728,366 | +12.7% | 1,349,503 | +65.0% | 0.00% | 0.0% |
| Q1 2023 | $18,392,885 | +57.3% | 817,825 | +47.1% | 0.00% | +100.0% |
| Q4 2022 | $11,691,376 | +9.5% | 555,938 | +28.3% | 0.00% | 0.0% |
| Q3 2022 | $10,680,000 | -15.9% | 433,418 | -17.3% | 0.00% | 0.0% |
| Q2 2022 | $12,704,000 | -17.7% | 524,297 | -12.5% | 0.00% | -50.0% |
| Q1 2022 | $15,433,000 | -2.8% | 598,877 | +17.1% | 0.00% | 0.0% |
| Q4 2021 | $15,873,000 | -31.5% | 511,370 | -46.5% | 0.00% | 0.0% |
| Q3 2021 | $23,169,000 | -5.0% | 955,430 | -42.9% | 0.00% | -33.3% |
| Q2 2021 | $24,400,000 | -59.9% | 1,672,485 | -31.3% | 0.00% | -57.1% |
| Q1 2021 | $60,828,000 | -7.0% | 2,436,071 | +1.6% | 0.01% | -12.5% |
| Q4 2020 | $65,375,000 | – | 2,398,633 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |